> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Vir Stock Soars 12% After Hepatitis Delta Trial Meets Its Main Goal
- URL: https://www.bullished.co/vir-stock-soars-12-after-hepatitis-delta-trial-meets-its-main-goal-911f982b/
- Published: 2026-11-09T14:49:22.000Z
- Updated: 2026-11-09T14:49:22.000Z
- Description: The gain added $259 million in market value, extending a run that had already put shares up 103% this year through Friday.
- Author: Matteo Parrino
- Tags: Markets, VIR, Industry: Healthcare

[Vir Biotechnology](https://www.bullished.co/tag/vir/), which develops experimental medicines for infectious diseases and cancer, soared 12.37% to $13.72 in Monday trading, as of 9:47 AM ET, adding $259 million in market value. The advance followed Sunday's announcement that its experimental hepatitis delta treatment [met the main goal](https://seekingalpha.com/news/4668779-vir-biotechnology-reports-positive-hepatitis-results-early-signs-of-possible-cure?ref=bullished.co) of a late-stage trial.

## Undetectable Virus In 79%

Vir reported [undetectable virus levels](https://finance.yahoo.com/markets/stocks/articles/vir-biotechnology-stock-jumps-22-130631799.html?ref=bullished.co) in 79% of treated patients after 48 weeks. The comparison group, whose treatment was delayed, registered 0% when assessed before treatment at 12 weeks—a different assessment period.

The study enrolled [124 patients](https://www.fiercebiotech.com/biotech/virs-phase-3-hepatitis-delta-win-fuels-push-eclipse-gilead?ref=bullished.co) and recorded one severe treatment-related adverse event. No patients interrupted or discontinued treatment.

The combination pairs elebsiran with tobevibart in a monthly injection. Vir's Wednesday earnings release described the trial as testing the combination against deferred treatment in the U.S. and other regions where bulevirtide use is limited.

## A Rally Already Up 103%

Vir reached a new 52-week high in Monday trading, as of 9:47 AM ET, and was on pace for its second gain of 10% or more this month. Its total market value stood at about $2.35 billion in Monday trading, as of 9:47 AM ET.

Before Monday's advance, shares had gained 103% this year through Friday's close, compared with 8% for the S&P 500\. That run came before confirmation of the hepatitis delta results management had been awaiting.

“We are entering an [important period for](https://www.sec.gov/Archives/edgar/data/0001706431/000162828026070148/a20261104-q3ex991earningsr.htm?ref=bullished.co) Vir Bio, with meaningful catalysts across both hepatitis delta and oncology,” Marianne De Backer, president and chief executive officer of Vir Biotechnology, said in Wednesday's earnings release.

## More Trials Before An Approval Bid

Vir expects results from two additional pivotal hepatitis delta trials in the first quarter of 2027\. It plans to [seek U.S. approval](https://seekingalpha.com/news/4668779-vir-biotechnology-reports-positive-hepatitis-results-early-signs-of-possible-cure?ref=bullished.co) in mid-2027; data from all three trials are intended for a global application package.

Vir's medicines remain development candidates rather than products approved for sale. Beyond infectious diseases, it develops cancer treatments, uses its dAIsY artificial-intelligence engine to engineer antibodies, and licenses candidates both into and out of its pipeline.

The company also expects pivotal trials of its prostate cancer candidate VIR-5500 to begin in 2027 with Astellas. The program received FDA Fast Track designation, and Vir said it achieved proof of concept.

Vir reported [negative revenue](https://www.sec.gov/Archives/edgar/data/1706431/000162828026070273/vir-20260930.htm?ref=bullished.co) of $188,000 and a $96.3 million net loss for the third quarter. It ended the quarter with approximately $901 million in cash, cash equivalents and investments, excluding $90 million in upfront consideration from its Gilead collaboration to develop three cancer-treatment candidates.

The next hepatitis delta readouts are expected in the first quarter of 2027, ahead of Vir's planned mid-2027 U.S. approval application.

### Sources

- [Vir Biotechnology stock jumps 22% after hepatitis delta Phase 3 trial success](https://finance.yahoo.com/markets/stocks/articles/vir-biotechnology-stock-jumps-22-130631799.html?ref=bullished.co) — Yahoo Finance
- [Vir’s phase 3 hepatitis delta win fuels push to eclipse Gilead | Fierce Biotech](https://www.fiercebiotech.com/biotech/virs-phase-3-hepatitis-delta-win-fuels-push-eclipse-gilead?ref=bullished.co) — fiercebiotech.com
- [VIR Stock Soars Over 10% Overnight, Eyes Best Year Ever — Hepatitis Win Sparks Buyout Buzz And Bigger Bullish Bets](https://finance.yahoo.com/healthcare/articles/vir-stock-soars-over-10-055942466.html?ref=bullished.co) — Yahoo Finance
- [Vir Biotechnology reports positive hepatitis results, early signs of possible cure (VIR:NASDAQ) | Seeking Alpha](https://seekingalpha.com/news/4668779-vir-biotechnology-reports-positive-hepatitis-results-early-signs-of-possible-cure?ref=bullished.co) — seekingalpha.com
- [Vir Stock Soars After Late-Stage Trial Win. Why Biotech Could Be Headed for the FDA](https://nz.finance.yahoo.com/news/vir-stock-soars-stage-trial-134528846.html?ref=bullished.co) — Yahoo Finance
- [The company's filing (Vir Biotechnology)](https://www.sec.gov/Archives/edgar/data/0001666306/000101297526001020/xslSCHEDULE%5F13D%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC filing
- [Vir Biotechnology — Form 10-Q for the quarter ended 2026-09-30 (quarterly results)](https://www.sec.gov/Archives/edgar/data/1706431/000162828026070273/vir-20260930.htm?ref=bullished.co) — SEC EDGAR
- [Vir Biotechnology — earnings release (Form 8-K, Item 2.02), filed 2026-11-04](https://www.sec.gov/Archives/edgar/data/0001706431/000162828026070148/a20261104-q3ex991earningsr.htm?ref=bullished.co) — SEC EDGAR

### More on Vir Biotechnology

- [ARCH Funds Sell 347,819 And 448,356 Vir Biotechnology Shares, Retain Stakes](https://www.bullished.co/arch-funds-sell-347-819-and-448-356-vir-biotechnology-shares-retain-stakes-48400650/)
- [Vir Biotechnology Trims Quarterly Loss To $96.3 Million As Hepatitis Delta Readout Nears](https://www.bullished.co/vir-biotechnology-trims-quarterly-loss-to-96-3-million-as-hepatitis-delta-readout-nears-31a3f585/)
- [Vir CEO Says Hepatitis Delta Combo Could Be 'Best-In-Class' As Rival's Phase 3 Data Land](https://www.bullished.co/vir-ceo-says-hepatitis-delta-combo-could-be-best-in-class-as-rivals-phase-3-data-land-21ad549a/)

[All Vir Biotechnology (VIR) coverage →](https://www.bullished.co/tag/vir/)